SG Americas Securities LLC Increases Stake in Aduro BioTech Inc (NASDAQ:ADRO)

Share on StockTwits

SG Americas Securities LLC grew its holdings in Aduro BioTech Inc (NASDAQ:ADRO) by 45.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 23,200 shares of the biotechnology company’s stock after buying an additional 7,283 shares during the period. SG Americas Securities LLC’s holdings in Aduro BioTech were worth $92,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Aduro BioTech by 138.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,402 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 7,202 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Aduro BioTech by 2,060.2% in the first quarter. BNP Paribas Arbitrage SA now owns 13,631 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 13,000 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Aduro BioTech in the fourth quarter valued at about $59,000. Bailard Inc. purchased a new stake in shares of Aduro BioTech in the first quarter valued at about $100,000. Finally, Legal & General Group Plc raised its holdings in shares of Aduro BioTech by 25.6% in the fourth quarter. Legal & General Group Plc now owns 30,303 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,184 shares during the last quarter. 41.97% of the stock is owned by institutional investors and hedge funds.

NASDAQ ADRO opened at $1.84 on Thursday. The stock has a market cap of $149.68 million, a P/E ratio of -1.59 and a beta of 2.10. Aduro BioTech Inc has a 52-week low of $1.70 and a 52-week high of $8.99. The company has a debt-to-equity ratio of 0.29, a current ratio of 9.11 and a quick ratio of 9.11.

Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.10). The firm had revenue of $3.94 million for the quarter, compared to analysts’ expectations of $8.08 million. Aduro BioTech had a negative return on equity of 63.81% and a negative net margin of 784.73%. As a group, sell-side analysts predict that Aduro BioTech Inc will post -0.83 EPS for the current fiscal year.

In related news, CFO Jennifer Lew sold 18,602 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $4.20, for a total transaction of $78,128.40. Following the completion of the transaction, the chief financial officer now directly owns 139,381 shares of the company’s stock, valued at $585,400.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 45,284 shares of company stock valued at $184,335 over the last three months. 5.20% of the stock is currently owned by corporate insiders.

ADRO has been the subject of a number of research reports. BidaskClub raised shares of Aduro BioTech from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. Oppenheimer reaffirmed a “buy” rating on shares of Aduro BioTech in a report on Tuesday, March 19th. Leerink Swann initiated coverage on shares of Aduro BioTech in a report on Monday, April 15th. They issued an “outperform” rating for the company. Svb Leerink reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Aduro BioTech in a report on Monday, April 15th. Finally, ValuEngine cut shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $7.68.

COPYRIGHT VIOLATION NOTICE: This report was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/4370120/sg-americas-securities-llc-increases-stake-in-aduro-biotech-inc-nasdaqadro.html.

About Aduro BioTech

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.

Recommended Story: Capital Gains Distribution

Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro BioTech Inc (NASDAQ:ADRO).

Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CVS Health Corp  Holdings Raised by Ironwood Investment Counsel LLC
CVS Health Corp Holdings Raised by Ironwood Investment Counsel LLC
Walmart Inc  Holdings Lifted by Meag Munich Ergo Kapitalanlagegesellschaft MBH
Walmart Inc Holdings Lifted by Meag Munich Ergo Kapitalanlagegesellschaft MBH
Rhumbline Advisers Has $423,000 Stake in Liberty Braves Group Series A
Rhumbline Advisers Has $423,000 Stake in Liberty Braves Group Series A
SG Americas Securities LLC Increases Stake in Aduro BioTech Inc
SG Americas Securities LLC Increases Stake in Aduro BioTech Inc
Magnachip Semiconductor  Raised to “Buy” at ValuEngine
Magnachip Semiconductor Raised to “Buy” at ValuEngine
Clarius Group LLC Takes Position in iShares Core High Dividend ETF
Clarius Group LLC Takes Position in iShares Core High Dividend ETF


© 2006-2019 Ticker Report